Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for treatment of glioblastoma is a research paper published in Neuro-Oncology (2022). On theSindex it has a DataRank of 0. It has been cited 144 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01CA155769
National Institutes of Health
Grant: R01CA236500
National Institutes of Health
Grant: R01CA254271
California Institute of Regenerative Medicine
Grant: CLIN2-10248
National Cancer Institute
Grant: P30CA033572
MeSH Terms
Keywords
Additional file 1 of Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation
Additional file 1 of Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation
Additional file 2 of Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation
Additional file 2 of Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation